Effectiveness and cost effectiveness of single bolus treatment with abciximab (Reo Pro) in preventing restenosis following percutaneous transluminal coronary angioplasty in high risk patients

摘要

Conclusions-At up to six months abcixi- mab offers improvements in clinically important outcomes. A modelling exer- cise explores and highlights the likelihood of significant long term health benefits. The analysis provides information for Decision makers and funders to consider The value for money of abciximab. Objective-To assess the clinical effective- Ness and cost effectiveness of abciximab in Preventing restenosis after percutaneous Transluminal coronary angioplasty (PTCA).